Welcome to the UPF Digital Repository

Evaluation of computationally designed peptides against TWEAK, a cytokine of the tumour necrosis factor ligand family

Show simple item record

dc.contributor.author Badia Villanueva, Miriam
dc.contributor.author Defaus, Sira
dc.contributor.author Foj, Ruben
dc.contributor.author Andreu Martínez, David
dc.contributor.author Oliva Miguel, Baldomero
dc.contributor.author Sierra, Angels
dc.contributor.author Fernández Fuentes, Narcís
dc.date.accessioned 2021-02-15T06:48:14Z
dc.date.available 2021-02-15T06:48:14Z
dc.date.issued 2021
dc.identifier.citation Badia-Villanueva M, Defaus S, Foj R, Andreu D, Oliva B, Sierra A, Fernandez-Fuentes N. Evaluation of computationally designed peptides against TWEAK, a cytokine of the tumour necrosis factor ligand family. Int J Mol Sci. 2021; 22(3):1066. DOI: 10.3390/ijms22031066
dc.identifier.issn 1422-0067
dc.identifier.uri http://hdl.handle.net/10230/46472
dc.description.abstract The tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor ligand family and has been shown to be overexpressed in tumoral cells together with the fibroblast growth factor-inducible 14 (Fn14) receptor. TWEAK-Fn14 interaction triggers a set of intracellular pathways responsible for tumour cell invasion and migration, as well as proliferation and angiogenesis. Hence, modulation of the TWEAK-Fn14 interaction is an important therapeutic goal. The targeting of protein-protein interactions by external agents, e.g., drugs, remains a substantial challenge. Given their intrinsic features, as well as recent advances that improve their pharmacological profiles, peptides have arisen as promising agents in this regard. Here, we report, by in silico structural design validated by cell-based and in vitro assays, the discovery of four peptides able to target TWEAK. Our results show that, when added to TWEAK-dependent cellular cultures, peptides cause a down-regulation of genes that are part of TWEAK-Fn14 signalling pathway. The direct, physical interaction between the peptides and TWEAK was further elucidated in an in vitro assay which confirmed that the bioactivity shown in cell-based assays was due to the targeting of TWEAK. The results presented here are framed within early pre-clinical drug development and therefore these peptide hits represent a starting point for the development of novel therapeutic agents. Our approach exemplifies the powerful combination of in silico and experimental efforts to quickly identify peptides with desirable traits.
dc.description.sponsorship The authors received support from the Spanish Ministry of Science (MINECO) [RYC2015-17519, BIO2017-83591-R, BIO2014-57518R, BIO2017-85329-R, AGL2013-48923-C2 and AGL2017-89097-C2-R2], the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) [FIS-PI14/00336 and FIS-PI18/00916], the EU Action NADIR FP7-228394 and the Maria de Maeztu Program for Center of Excellence program (AEI CEX2018-000792-M.).
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof Int J Mol Sci. 2021; 22(3):1066
dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Evaluation of computationally designed peptides against TWEAK, a cytokine of the tumour necrosis factor ligand family
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/ijms22031066
dc.subject.keyword TWEAK
dc.subject.keyword Expression microarrays
dc.subject.keyword Orthosteric peptides
dc.subject.keyword Peptide design
dc.subject.keyword Protein-protein interactions
dc.subject.keyword Surface plasmon resonance
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/228394
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/RYC2015-17519
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/BIO2017-83591-R
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/BIO2014-57518-R
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/BIO2017-85329-R
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/AGL2013-48923-C2
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/AGL2017-89097-C2-R2
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking